Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
2000 3
2003 1
2005 1
2007 1
2009 1
2011 3
2012 3
2013 5
2014 1
2015 3
2016 4
2017 2
2018 1
2020 1
2021 2
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
What We Know about and What Is New in Primary Aldosteronism.
Ekman N, Grossman AB, Dworakowska D. Ekman N, et al. Int J Mol Sci. 2024 Jan 11;25(2):900. doi: 10.3390/ijms25020900. Int J Mol Sci. 2024. PMID: 38255973 Free PMC article. Review.
The principal aetiologies of PA include bilateral idiopathic hypertrophy (BIH) and aldosterone-producing adenomas (APAs), while the less frequent causes include unilateral hyperplasia, familial hyperaldosteronism (FH) types I-IV, aldosterone-producing carcinoma, and …
The principal aetiologies of PA include bilateral idiopathic hypertrophy (BIH) and aldosterone-producing adenomas (APAs), while the less fre …
Therapeutic management of congenital forms of endocrine hypertension.
Charoensri S, Auchus RJ. Charoensri S, et al. Eur J Endocrinol. 2023 Nov 8;189(5):R11-R22. doi: 10.1093/ejendo/lvad140. Eur J Endocrinol. 2023. PMID: 37847213 Review.
This review article summarizes the current state of knowledge on the therapeutic management of congenital forms of endocrine hypertension, focusing on familial hyperaldosteronism (FH), congenital adrenal hyperplasia, apparent mineralocorticoid excess, and Liddle syn …
This review article summarizes the current state of knowledge on the therapeutic management of congenital forms of endocrine hypertension, f …
Primary aldosteronism.
Gordon RD. Gordon RD. J Endocrinol Invest. 1995 Jul-Aug;18(7):495-511. doi: 10.1007/BF03349761. J Endocrinol Invest. 1995. PMID: 9221268 Review.
In all patients with PAL confirmed by lack of suppressibility ("autonomy") of aldosterone production, Familial Hyperaldosteronism Type I (FH-I, glucocorticoid-remediable hyperaldosteronism, reviewed elsewhere in this issue) should first be excluded by dexamethasone …
In all patients with PAL confirmed by lack of suppressibility ("autonomy") of aldosterone production, Familial Hyperaldosteronism …
Genetics of primary aldosteronism.
Vaidya A, Hamrahian AH, Auchus RJ. Vaidya A, et al. Endocr Pract. 2015 Apr;21(4):400-5. doi: 10.4158/EP14512.RA. Epub 2015 Feb 9. Endocr Pract. 2015. PMID: 25667376 Free PMC article. Review.
The genetics of PA are rapidly evolving, and the consideration for genetic causes of PA are growing. Three inheritable forms of PA are now recognized: familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism), familial hyperaldosteronism …
The genetics of PA are rapidly evolving, and the consideration for genetic causes of PA are growing. Three inheritable forms of PA are now r …
Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.
Tan ST, Boyle V, Elston MS. Tan ST, et al. Hypertension. 2023 Jul;80(7):1517-1525. doi: 10.1161/HYPERTENSIONAHA.123.21054. Epub 2023 May 12. Hypertension. 2023. PMID: 37170822
BACKGROUND: Familial hyperaldosteronism type 1 (FH1), previously known as glucocorticoid-remediable aldosteronism, was the first identified monogenic cause of primary aldosteronism. ...
BACKGROUND: Familial hyperaldosteronism type 1 (FH1), previously known as glucocorticoid-remediable aldosteronism, was the fir …
Genetic disorders in primary aldosteronism-familial and somatic.
Funder JW. Funder JW. J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):154-157. doi: 10.1016/j.jsbmb.2016.03.020. Epub 2016 Mar 21. J Steroid Biochem Mol Biol. 2017. PMID: 27013018 Review.
Familial hyperaldosteronism has been with us for 50 years, and somatic mutations responsible for aldosterone producing adenomas for five. ...
Familial hyperaldosteronism has been with us for 50 years, and somatic mutations responsible for aldosterone producing adenoma …
Management and Outcomes of Primary Aldosteronism in Pregnancy: A Systematic Review.
Sanga V, Rossitto G, Seccia TM, Rossi GP. Sanga V, et al. Hypertension. 2022 Sep;79(9):1912-1921. doi: 10.1161/HYPERTENSIONAHA.121.18858. Epub 2022 Jun 10. Hypertension. 2022. PMID: 35686552 Free article. Review.
Results showed that complications involved 62.2% of pregnant women with nonfamilial PA and 18.5% of those with familial hyperaldosteronism type I. Adrenalectomy during pregnancy in women with PAP did not improve maternal and fetal outcomes, over medical treatment al …
Results showed that complications involved 62.2% of pregnant women with nonfamilial PA and 18.5% of those with familial hyperaldos …
Hyperplasia in glands with hormone excess.
Marx SJ. Marx SJ. Endocr Relat Cancer. 2016 Jan;23(1):R1-14. doi: 10.1530/ERC-15-0171. Epub 2015 Sep 25. Endocr Relat Cancer. 2016. PMID: 26407873 Free PMC article. Review.
Five syndromes share predominantly hyperplastic glands with a primary excess of hormones: neonatal severe primary hyperparathyroidism, from homozygous mutated CASR, begins severely in utero; congenital non-autoimmune thyrotoxicosis, from mutated TSHR, varies from severe with feta …
Five syndromes share predominantly hyperplastic glands with a primary excess of hormones: neonatal severe primary hyperparathyroidism, from …
Heritable forms of hypertension.
Vehaskari VM. Vehaskari VM. Pediatr Nephrol. 2009 Oct;24(10):1929-37. doi: 10.1007/s00467-007-0537-8. Epub 2007 Jul 24. Pediatr Nephrol. 2009. PMID: 17647025 Free PMC article. Review.
The pathophysiology may involve inappropriate production of aldosterone [in glucocorticoid-remediable aldosteronism (GRA) and familial hyperaldosteronism type II (FH II)], of cortisol (in familial glucocorticoid resistance), or of other steroid metabolites (in conge …
The pathophysiology may involve inappropriate production of aldosterone [in glucocorticoid-remediable aldosteronism (GRA) and familial …
The genetic basis of primary aldosteronism.
Funder JW. Funder JW. Curr Hypertens Rep. 2012 Apr;14(2):120-4. doi: 10.1007/s11906-012-0255-x. Curr Hypertens Rep. 2012. PMID: 22359160 Review.
Primary aldosteronism is commonly regarded as largely sporadic, but both germline and somatic mutations are increasingly recognized as underlying the condition. Three germline mutations causing familial hyperaldosteronism have been described, dubbed FH I (due to a C …
Primary aldosteronism is commonly regarded as largely sporadic, but both germline and somatic mutations are increasingly recognized as under …
36 results